Format

Send to

Choose Destination
Vaccine. 2017 Aug 16;35(35 Pt B):4532-4539. doi: 10.1016/j.vaccine.2017.07.032. Epub 2017 Jul 23.

Targeting interferon-alpha to dendritic cells enhances a CD8+ T cell response to a human CD40-targeted cancer vaccine.

Author information

1
The Ralph Steinman Center for Cancer Vaccines, Baylor Institute for Immunology Research, Baylor Scott and White Research Institute, Dallas, TX 75204, USA.
2
The Ralph Steinman Center for Cancer Vaccines, Baylor Institute for Immunology Research, Baylor Scott and White Research Institute, Dallas, TX 75204, USA; Vaccine Research Institute, Université Paris-Est, Faculté de Médecine, INSERM U955, USA. Electronic address: gerardz@baylorhealth.edu.

Abstract

Targeting antigens to antigen presenting cells (APC) enhances the potency of recombinant protein CD8+ T cell vaccines. Recent comparisons of recombinant protein-based dendritic cell (DC) targeting vaccines revealed differences in cross-presentation and identified CD40 as a potent human DC receptor target for antigen cross-presentation. Contrary to in vitro-derived monocyte (mo)DC, we found that interferon-alpha (IFNα) stimulation of human blood-derived DC was necessary for an antigen-specific IFNγ CD8+ T cell response to a CD40 targeted cancer vaccine. Importantly, targeting an adjuvant in the form of IFNα to DC increased their potency to elicit antigen-specific production of IFNγ by CD8+ T cells. Thus, we introduce the concept of DC adjuvant targeting to enhance the potency of vaccination.

KEYWORDS:

Adjuvant; CD8(+) T cells; Cancer vaccine; Dendritic cells; Interferon-alpha

PMID:
28743486
DOI:
10.1016/j.vaccine.2017.07.032
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center